Friday, 10 April 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 10 April 2026
News

Pharmac funds time-saving meds

Posted 10 April 2026 AM

Pharmac has announced new funding for cancer drugs and an antiviral, with the listings expected to ease pressure on the hospital system by reducing the time spent there.

From 1 May treatment options for people living with chronic lymphocytic leukaemia (CLL) will be expanded, with AbbVie's Venclexta funded in combination with Johnson & Johnson's Imbruvica or Roche's Gazyva as a first line treatment option for CLL. Further, access to Imbruvica will be widened as a second line treatment regardless of a patient's specific mutation.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (2)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.